Wolverine Asset Management’s enGene Therapeutics Warrants ENGNW Stock Holding History
Bought
Maintained
Sold
Other funds holding ENGNW
Wolverine Asset Management's ENGNW Position: Q3 2026 in Review
Wolverine Asset Management opened a new position in enGene Therapeutics Warrants (ENGNW) in Q3 2026: 1,344 shares worth $269. The stake represents ﹤0.01% of the portfolio and ranks #1697 among its holdings. This is a return to the name: Wolverine Asset Management previously reported a position in ENGNW as recently as Q4 2025.
Wolverine Asset Management first reported a position in ENGNW in Q4 2023 and has held it in 7 quarters since. The position peaked at $66K in Q1 2024. 2 funds tracked by Wall St. Rank hold ENGNW as of Q3 2026.
- Wolverine Asset Management held 1,344 shares of enGene Therapeutics Warrants worth $269 as of Q3 2026.
- enGene Therapeutics Warrants was a new Wolverine Asset Management position in Q3 2026.
- enGene Therapeutics Warrants made up ﹤0.01% of Wolverine Asset Management's portfolio in Q3 2026, its #1697 holding.
- Wolverine Asset Management first reported a position in enGene Therapeutics Warrants in Q4 2023 and has held it in 7 quarters since.
- Wolverine Asset Management's enGene Therapeutics Warrants position peaked at $66K in Q1 2024.
- 2 funds tracked by Wall St. Rank held enGene Therapeutics Warrants as of Q3 2026.
Based on Wolverine Asset Management's 13F filing for Q3 2026, filed 2 Nov 2026.